ASP Isotopes Inc

ASP Isotopes develops and operates laser-based enrichment systems to produce uranium-235 and stable isotopes for nuclear fuel and medical applications. Its proprietary quantum enrichment process aims to lower energy intensity and capital costs relative to traditional centrifuge or gaseous diffusion methods, positioning the company as a potential supplier of low-enriched uranium and high-assay LEU for advanced reactors.

In the past year the firm signed a term sheet with a U.S. utility for future HALEU supply and began construction of a pilot enrichment facility in South Africa. Key risks include unproven commercial-scale performance of the laser technology, dependence on securing long-term offtake contracts, and exposure to U.S. and South African regulatory approvals that could delay or limit market access.

AI-generated brief · refreshed 2 days ago